A review of carvedilol arrhythmia data in clinical trials

Peter R Kowey1

  • 1Division of Cardiovascular Diseases, Main Line Health Heart Center, Wynnewood, PA, Philadelphia, PA 19096, USA. koweypr@mlhheart.org

Insights

Carvedilol effectively controls atrial fibrillation and reduces mortality in heart failure and post-myocardial infarction patients. This beta-blocker also lowers the risk of ventricular arrhythmias and sudden cardiac death.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Beta-blockers are investigated for antiarrhythmic properties.
  • Not all beta-blockers demonstrate equal efficacy in clinical trials.
  • Carvedilol, a third-generation beta-blocker, shows promise as an antiarrhythmic agent.

Purpose of the Study:

  • To review clinical arrhythmia data for carvedilol.
  • To evaluate carvedilol's effectiveness in various cardiac conditions.
  • To assess its role in managing arrhythmias and sudden death.

Main Methods:

  • Review of large-scale clinical trials and smaller studies on carvedilol.
  • Analysis of data concerning atrial fibrillation and ventricular arrhythmias.
  • Evaluation of mortality benefits in heart failure and post-myocardial infarction patients.

Main Results:

  • Carvedilol serves as effective adjunctive rate-control therapy for atrial fibrillation.
  • It prevents mortality in heart failure and post-MI patients with left ventricular dysfunction.
  • Carvedilol reduces the incidence of ventricular arrhythmias and sudden death.

Conclusions:

  • Carvedilol demonstrates significant antiarrhythmic and mortality-reducing benefits.
  • Its efficacy extends to patients with and without atrial fibrillation.
  • Carvedilol is a valuable therapeutic option in managing complex cardiac conditions.

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...